Compare Heron Therapeutics Inc (HRTX) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Vanguard High Dividend Yield ETF — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while Vanguard High Dividend Yield ETF trades at $160. The key difference: Vanguard High Dividend Yield ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | VYM | |
|---|---|---|
Market Cap | $91.46M | — |
Sector | Health | — |
52-Week High | $1.96 | $161.17 |
52-Week Low | $0.39 | $132.90 |
Enterprise Value | $189.36M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
VYM trades at $159.41, down 0.47% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF holds $94.6 billion in assets, emphasizing high dividend yield from U.S. large-cap stocks. Recent news highlights institutional buying and its role in retirement income strategies, with a dividend of $0.98 scheduled for June 2026.
Outlook remains positive for income-focused investors due to broad diversification and low costs, though risks include interest rate sensitivity and market volatility. The ETF's appeal lies in steady cash flow, but competition from higher-yielding funds poses a challenge to outperformance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →
